Market News & Trends
Avidity Announces Positive AOC 1001 Phase 1/2 MARINA Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics
Avidity Biosciences, Inc. recently announced positive AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever….
Hovione & GEA announce a Strategic Collaboration to Advance Continuous Tableting
Hovione & GEA recently announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years….
Syneos Health Extends Partnership With Medable; Continued Collaboration Will Accelerate Bringing Clinical Trials Closer to the Patient
Syneos Health recently announced it has extended its strategic partnership with Medable, the industry-leading technology platform for patient-centered clinical trials, as part of….
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
Immix Biopharma, Inc. recently announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the 15 patient dosed with IMX-110 to-date.…
Sosei Heptares Receives $10-Million Milestone Payment in Discovery Collaboration With AbbVie Targeting Inflammatory Diseases
Sosei Group Corporation recently announced it has reached an important R&D milestone under its discovery collaboration with AbbVie, the global biopharmaceutical company, focused on inflammatory and autoimmune….
Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation & Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc. recently announced the initiation of INDP-D101, its first-in-human, open-label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound…
Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction & Progression Free Survival Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model
Starton Therapeutics Inc. recently announced results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant…
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
Lantheus Holdings, Inc. recently announced a strategic collaboration with SonoThera, Inc. in which Lantheus’ microbubbles will be used in combination with SonoThera’s ultrasound-guided, nonviral, gene…
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-Derived Allogeneic CAR-NK Cell Therapy
Caribou Biosciences, Inc. recently announced target selection for CB-020, an induced pluripotent stem cell (iPSC)-derived allogeneic anti-ROR 1 (receptor tyrosine kinase like orphan receptor 1)…
UM171 Cell Therapy Demonstrates Improved Outcomes Compared to Cord & Matched Unrelated Donor Peripheral Blood Transplants in Real-World Setting
ExCellThera Inc. recently announced findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with….
FDA Accepts Biogen Biologics License Application for Biosimilar Candidate Referencing ACTEMRA (tocilizumab)
Biogen Inc. recently announced the US FDA has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA (tocilizumab),…
Quotient Sciences Celebrates Grand Opening of New Drug Substance Facility with Official Ribbon Cutting
Quotient Sciences, the drug development and manufacturing accelerator, will hold an official ribbon cutting event in celebration of the grand opening of their new drug…
Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Belgium
Catalent recently announced the completion and opening of a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies in….
Metrion Biosciences & The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder
Metrion Biosciences Limited and The KCNC1 Foundation recently announced a collaboration to progress a hit identification research project for small molecule modulators of the….
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
VYNE Therapeutics Inc. recently announced GB Patent No. 2597228, titled Compounds Comprising N-Methyl-2-Pyridone, And Pharmaceutically Acceptable Salts, has been granted by the United Kingdom’s Intellectual Property…
Esperion Announces CLEAR Cardiovascular Outcomes Trial Meets Primary Endpoint
Esperion recently announced the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction…
Gerresheimer to Expand Significantly in High Value Solutions & Further Accelerates its Sustainable Profitable Growth
Gerresheimer AG recently reaffirmed its growth agenda and increased its revenue and adjusted EBITDA guidance. The company continues to execute consistently its formula g strategy…
Summit Therapeutics Partners With Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
Summit Therapeutics Inc. recently announced a definitive agreement of its partnership with Akeso Inc. to in-license its breakthrough bispecific antibody, ivonescimab…..
Evonik Launches Plant-Based Squalene to Boost Vaccine Efficacy
Evonik has recently launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene on the market…
Incannex Expands Intellectual Property Position Over IHL-42X
Incannex Healthcare Limited recently announced the filing of a provisional patent application directed to the use of IHL-42X for the treatment of Obstructive Sleep Apnoea….
